curis????????????????????? - 500 Beiträge pro Seite

[wings111]

Wer hat neue Infos zu Curis???

Kurs -30%

Viele Grüße

[Steve de Ville]

hi

leider auch keine Ahnung
nachbörslich bei einem Umsatz von 2800 Stück !!!!!!
von 13 auf 8,5 Dollar
keine News
totale Ratlosigkeit

mal schaun, ein Grung musses ja wohl geben.

[Steve de Ville]

hi
hier mal der nachbörsliche Kurs

After Hours Trade Reporting
Monday January 29 After Hours Most Active
After Hours
Last: $8.875 After Hours
Best Bid: $8.1875 After Hours
High: $13.25
After Hours
Volume: 2,800 After Hours
Best Ask: $8.875 After Hours
Low: $8.875

After Hours
Time (ET) After Hours
Price After Hours
Share Volume
18.14 $ 8.875 100
17.41 $ 9.6875 100
17.23 $ 10 300
17.14 $ 10.8125 100
17.12 $ 10.8125 300
17.12 $ 10.8281 300
17.10 $ 11 300
17.03 $ 11.25 200
16.59 $ 11.75 300
16.59 $ 11.7656 100
16.59 $ 11.7656 200
16.01 $ 13.25 500 !!! ++

ich hoffe es handelt sich nur um einen Scherz
wenn auch um einen üblen

gruß

[wings111]

Auf diesem Board wurde einmal etwas von einem Splitt geschrieben?????? Vielleicht gestern???

Meldet Euch bitte!! sonst habt ihr doch auch schnell die Info`s???


Danke!

[Steve de Ville]

von Splitt wurde meinen Infos nach
noch nicht gesprochen
würde eigentlich zur Zeit
auch keinen Sinn machen

gruß Steve de Ville

[Steve de Ville]

bei diesem Kursrutsch
handelt es sich devinitiv um
keinen Splitt !!!!
( falls du dies damit gemeint hast )

[heide1]

Den Grund findet Ihr ab Absatz 4:

UPDATE 2-Stryker Q4 profits rise 27 percent (Recasts, adds details about FDA
non-approval action)

NEW YORK, Jan 29 (Reuters) - Medical products maker Stryker Corp. <SYK.N> on
Monday reported a 27 percent increase in its fourth-quarter profit, boosted by surgical
equipment sales and its fast-growing physical therapy services unit, but said U.S. regulators had
not approved the company`s experimental implant to treat leg fractures.

The Kalamazoo, Mich.-based manufacturer of specialty surgical products said operating
earnings were $65.8 million, or 33 cents per share, in the latest quarter, up from $51.7 million, or
26 cents per share a year ago, excluding one-time items in both periods.

Analysts were expecting, on average, a profit of 33 cents per share, according to First
Call/Thomson Financial.

The company also said on Monday the U.S. Food and Drug Administration decided not to
approve the company`s OP-1 Implant for treating fractures of the tibia, the inner and the larger of
the two bones of the lower leg, extending from the knee to the ankle.

The company said the deficiencies cited by the FDA stem from the clinical trials of the product.
In the tests, the treatment failed to show a statistical equivalence compared with the control
treatment, which was "autograft," or tissue that is taken from one place on a person`s body and
attached to another site on the same person. SALES STRONGER

Stryker said net sales were $612.4 million for the fourth quarter of 2000, a 10 percent increase
over net sales of $559.1 million in the year-ago period. Excluding the impact of foreign currency
and discontinued products, net sales increased 14 percent for the fourth quarter.

Domestic sales jumped 18 percent to $380.9 million for the fourth quarter on strong shipments
of orthopedic implants, powered surgical instruments, endoscopic equipment, hospital beds and
stretchers and higher revenue from physical therapy services.

Stryker`s physical therapy services revenues soared 50 percent to $40.7 million. Worldwide
sales of MedSurg Equipment jumped 18 percent to $230.7 million in the period compared with
the year-ago quarter and global orthopedic implants sales edged up 1 percent to $341.0 million
in the period.

Stryker stock fell $1.33, or nearly 3 percent, to close at $46.95 on Monday on the New York
Stock Exchange, below a year high of $57.75 and above a 52-week low of $24.4375.

The stock is up 19 percent over the last 52-week period, but was outpaced by the Standard &
Poor`s medical device index`s <.SPMED> 24 percent rise over the same period. Stryker shares
have underperformed the Standard & Poor`s medical device index for most of the last 52 weeks,
and most recently lagged the gauge by about 4 percent. TWO STEPS FORWARD, ONE
STEP BACK

Despite the FDA`s decision on Monday to not approve Stryker`s experimental implant, the
company said the agency has asked it conduct a new study on the device to treat leg fractures.

The company said it intends to continue working with the FDA with the goal of getting its implant
device approved. Stryker, in a statement earlier Monday, said it would hold a meeting with the
FDA to discuss the agency`s Not-Approvable Letter.

"It`s not significant for Stryker in a revenues sense," said ABN Amro analyst Bruce Cranna,
explaining that many analysts had already excluded the potential sales from the implant treatment
from their financial forecasts for 2001.

"But it`s a negative from a psychological standpoint," he said.

The overall market for such devices to treat fractures of the tibia could be about $1 billion,
Cranna said.

Stryker said a key European regulatory body already has recommended approval of the OP-1
implant for marketing in the European Union.

((Edward Tobin and Jed Seltzer, New York Health Desk, 212 859 1870))

REUTERS

Rtr 19:38 01-29-01

Copyright 2001, Reuters News Service. All rights reserved. Replication or redistribution of Reuter

[wings111]

Die große Gretchen Frage??

Wohin soll der Kurs eigentlich noch sinken?? Bzw. Curis wird doch nicht nur auf diese Sache gesetzt haben????

Viele Grüße